Dr.Grigoriadis Ioannis

Biogenea Pharmaceuticals Ltd, Greece
Title: MicrocrylaqTM: A New Way to Implement Quantum Computation algebraic calculations in a 3D logical space for the discovery of a novel chemical antagonist against the two crizotinib-resistant ALK mutations, G1202R and F1174C in a MicrocrylaqTM Lindenbaum-Tarski based QSAR automating modeling lead compo


Dr Ioannis Grigoriadis is the CEO at Biogenea SA, Greece

Research Interest

Computer Drug Discovery Science

No Content found...